Batu Biologics Files Patent Covering New Use Of Approved Drug For Decreasing Cancer Immunotherapy Toxicity
5/12/2014 9:15:58 AM
SAN DIEGO--(BUSINESS WIRE)--Batu Biologics announced today filing of US patent #61/990231 covering the use of a commercially available drug, currently in use for other indications, for decreasing toxicity of immunotherapies such as interleukin-2. The patent is based on data demonstrating that the dosage of various cancer immune therapies is limited by toxicity of the therapy to the blood vessels of the patient, resulting in vascular leak syndrome, sepsis and death. Batu Biologics, through a series of in vitro and in vivo experiments, demonstrated that the dose of interleukin-2, a prototypic immunotherapy, can be increased by up to 100% when utilized together with the existing drug.
Help employers find you! Check out all the jobs and post your resume.
comments powered by